Janardan Pandey to Breast Neoplasms
This is a "connection" page, showing publications Janardan Pandey has written about Breast Neoplasms.
Connection Strength
2.335
-
IGHG, IGKC, and FCGR genes and endogenous antibody responses to GARP in patients with breast cancer and matched controls. Hum Immunol. 2018 Aug; 79(8):632-637.
Score: 0.305
-
Endogenous antibody responses to mucin 1 in a large multiethnic cohort of patients with breast cancer and healthy controls: Role of immunoglobulin and Fc? receptor genes. Immunobiology. 2018 02; 223(2):178-182.
Score: 0.292
-
Genetic markers of immunoglobulin G and immunity to cytomegalovirus in patients with breast cancer. Cell Immunol. 2017 02; 312:67-70.
Score: 0.273
-
Humoral Immunity to Cytomegalovirus Glycoprotein B in Patients With Breast Cancer and Matched Controls: Contribution of Immunoglobulin ?, ?, and Fc? Receptor Genes. J Infect Dis. 2016 Feb 15; 213(4):611-7.
Score: 0.253
-
IGKC and Fc?R genotypes and humoral immunity to HER2 in breast cancer. Immunobiology. 2014 Feb; 219(2):113-7.
Score: 0.219
-
Racially restricted contribution of immunoglobulin Fc? and Fc? receptor genotypes to humoral immunity to human epidermal growth factor receptor 2 in breast cancer. Clin Exp Immunol. 2013 Mar; 171(3):273-7.
Score: 0.212
-
Genetic markers of immunoglobulin G and susceptibility to breast cancer. Hum Immunol. 2012 Nov; 73(11):1155-8.
Score: 0.204
-
Comments on: Iwasaki et al. Fragment c gamma receptor gene polymorphisms and breast cancer risk in case-control studies in Japanese, Japanese Brazilians, and non-Japanese Brazilians. Breast Cancer Res Treat. 2011 Feb; 126(1):247-8; author reply 248.
Score: 0.180
-
Genetic regulation of antibody responses to human epidermal growth factor receptor 2 in breast cancer. Hum Immunol. 2010 Nov; 71(11):1124-7.
Score: 0.178
-
A genetic variant of immunoglobulin gamma2 is strongly associated with immunity to mucin 1 in patients with breast cancer. Cancer Immunol Immunother. 2009 Dec; 58(12):2025-9.
Score: 0.162
-
Higher levels of antibodies to the tumour-associated antigen cyclin B1 in cancer-free individuals than in patients with breast cancer. Clin Exp Immunol. 2014 Oct; 178(1):75-8.
Score: 0.059